High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults

Keitel, Wendy A.; Couch, Robert B.; Cate, Thomas R.; Hess, Kenneth R.; Baxter, Barbara; Quarles, John; Atmar, Robert L.; Six, Howard R.

doi:10.1128/jcm.32.10.2468-2473.1994

Cited by 63 publications

(28 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with the previously reported studies that showed that increased doses of purified HA and increased doses of subvirion vaccines result in an enhanced antibody response in both the elderly and the healthy adult population. 21,22 The TIV provides an economical and effective means to reduce the impact of an influenza infection. It is effective in the prevention of influenza in young adults with reported levels of protection as high as 70-90%; 23,24 however, only 30-50% of subjects older than 65 years vaccinated achieve protective titers against the H3 strain.…”

Section: Discussionmentioning

confidence: 99%

Production of a novel influenza vaccine using insect cells: protection against drifted strains

Cox¹,

Anderson²

2007

Influenza Resp Viruses

View full text Add to dashboard Cite

A recombinant trivalent hemagglutinin (HA) vaccine produced in cell culture using the baculovirus expression system provides an attractive alternative to the current egg‐based influenza vaccine (Trivalent Inactivated Influenza Vaccine [TIV]) manufacturing process. The HA genes from the annual World Health Organization‐recommended strains are cloned, expressed, and purified using a general purification process. Here, we provide an overview of the expression technology used to make the annual adjustment of the vaccine and the clinical studies completed to date with recombinant HA. The highly purified protein vaccine, administered at three times higher antigen content than TIV, results in stronger immunogenicity, a long‐lasting immune response and provides cross‐protection against drift variant influenza viruses. Furthermore, the vaccine does not contain egg proteins, adjuvants, preservatives, endotoxins, or antibiotics and can therefore be used in a broader population.

show abstract

Section: Discussionmentioning

confidence: 99%

Production of a novel influenza vaccine using insect cells: protection against drifted strains

Cox¹,

Anderson²

2007

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…Recently, improved purification techniques have allowed exploration of much higher doses of vaccine. Administration of 405 mg of highly purified monovalent H1 antigen to healthy young adults, or of trivalent vaccine containing 135 mg of each antigen was well-tolerated and produced 2-to 4-fold higher geometric mean serum HAI and neutralizing antibody titers 4 weeks after vaccination, compared with standard doses (Keitel et al, 1994). Improved nasal secretion antibody responses with high dose vaccines were also seen (Keitel et al, 1994).…”

Section: Vaccine De6elopmentmentioning

confidence: 96%

Respiratory viral infections in the elderly

Treanor

Falsey

1999

Antiviral Research

View full text Add to dashboard Cite

Viral respiratory infections represent a significant challenge for those interested in improving the health of the elderly. Influenza continues to result in a large burden of excess morbidity and mortality. Two effective measures, inactivated influenza vaccine, and the antiviral drugs rimantadine and amantadine, are currently available for control of this disease. Inactivated vaccine should be given yearly to all of those over the age of 65, as well as younger individuals with high-risk medical conditions and individuals delivering care to such persons. Live, intranasally administered attenuated influenza vaccines are also in development, and may be useful in combination with inactivated vaccine in the elderly. The antiviral drugs amantadine and rimantadine are effective in the treatment and prevention of influenza A, although rimantadine is associated with fewer side-effects. Recently, the inhaled neuraminidase inhibitor zanamivir, which is active against both influenza A and B viruses, was licensed for use in uncomplicated influenza. The role of this drug in treatment and prevention of influenza in the elderly remains to be determined. Additional neuraminidase inhibitors are also being developed. In addition, to influenza, respiratory infections with respiratory syncytial virus, parainfluenza virus, rhinovirus, and coronavirus have been identified as potential problems in the elderly. With increasing attention, it is probable that the impact of these infections in this age group will be more extensively documented. Understanding of the immunology and pathogenesis of these infections in elderly adults is in its infancy, and considerable additional work will need to be performed towards development of effective control measures.

show abstract

“…Serum specimens obtained at enrollment, acute and convalescent visits for illnesses, and the terminal visit were tested simultaneously using hemagglutination-inhibition (HAI) antibody tests following previously described methods [11,12]. Virus antigens were a locally obtained pH1N1 virus (A/Baylor/09) and the most recently prevalent seasonal A/H1N1 virus (A/Brisbane/59/07).…”

Section: Serologymentioning

confidence: 99%

Prior Infections With Seasonal Influenza A/H1N1 Virus Reduced the Illness Severity and Epidemic Intensity of Pandemic H1N1 Influenza in Healthy Adults

Couch¹,

Atmar²,

Franco³

et al. 2011

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults

Cited by 63 publications

References 26 publications

Production of a novel influenza vaccine using insect cells: protection against drifted strains

Production of a novel influenza vaccine using insect cells: protection against drifted strains

Respiratory viral infections in the elderly

Prior Infections With Seasonal Influenza A/H1N1 Virus Reduced the Illness Severity and Epidemic Intensity of Pandemic H1N1 Influenza in Healthy Adults

Contact Info

Product

Resources

About